Dr. Bivona is a medical oncologist with a PhD in cell and molecular biology. He maintains an active academic clinical practice in thoracic oncology and leads a basic and translational research laboratory focused on cancer genetics, precision medicine, and the molecular basis of targeted therapy response and resistance. His research efforts, in collaboration with numerous investigators, have led to the discovery of novel mechanisms of resistance to EGFR targeted therapy, BRAF and MEK targeted therapy, and ALK targeted therapy in lung cancer and other cancers, of specific synthetic lethal genetic interactions underlying new rational targeted polytherapy strategies, and of key mechanisms controlling RAS GTPase signaling in cells. He directs a multi-disciplinary team engaged in laboratory-based patient-focused research and is a leading investigator on clinical trials, including rational upfront polytherapy trials designed to forestall and eliminate resistance and that are motivated by the laboratory-based discoveries. Dr. Bivona’s collective efforts have resulted in important scientific contributions to signaling biology, genetics, cancer drug resistance, and precision cancer medicine.